Do DNA copy number changes differentiate uterine from non-uterine leiomyosarcomas and predict metastasis?

Modern Pathology

Volumn 19, Issue 8, 2006, Pages 1068-1082

  Svarvar, Catarina ^a,b   Larramendy, Marcelo L ^b,c   Blomqvist, Carl ^a   Gentile, Massimiliano ^b   Koivisto Korander, Riitta ^a   Leminen, Arto ^a   Bützow, Ralf ^a,b   Böhling, Tom ^b   Knuutila, Sakari ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c FACULTAD DE CIENCIAS NATURALES Y MUSEO   (Argentina)

Author keywords

Comparative genomic hybridization; DNA copy number changes; Leiomyosarcoma; Metastasis

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CHROMOSOME 10Q; CHROMOSOME 13Q; CHROMOSOME 16Q; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CHROMOSOME GAIN; CHROMOSOME LOSS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENOMIC IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MALE; METASTASIS; PRIORITY JOURNAL; UTERUS SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; DNA, NEOPLASM; FEMALE; GENE DOSAGE; GENETIC MARKERS; HUMANS; LEIOMYOSARCOMA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NUCLEIC ACID HYBRIDIZATION; PROGNOSIS; RETROSPECTIVE STUDIES; UTERINE NEOPLASMS;

EID: 33746317753     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800617     Document Type: Article

References (69)

1. Weiss SW, Goldblum JR. Leiomyosarcoma. In: Weiss SW, Goldblum JR (eds). Enzinger and Weiss's Soft Tissue Tumors, 4th edn. Mosby Harcourt: Philadel phia, 2001, pp 727-748.
2. Miettinen M. Smooth muscle tumors. In: Miettinen M (ed). Diagnostic soft tissue pathology. 1st edn. Churchill Livingstone: Philadelphia, 2003, pp 241-258.
3. Evans HL, Shipley J. Leiomyosarcoma. In: Fletcher CDM, Unni KK, Mertens F (eds). World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press: Lyon, 2002, pp 131-134.
4. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956-1992: Incidence, survival and mortality. Eur J Cancer 1997;33:907-911.
5. Benoit L, Arnould L, Cheynel N, et al. The role of surgery and treatment trends in uterine sarcoma. Eur J Surg Oncol 2005;31:434-442.
6. Hashimoto H, Daimaru Y, Tsuneyoshi M, et al. Leiomyosarcoma of the external soft tissues. A clinicopathologic, immunohistochemical, and electron microscopic study. Cancer 1986;57:2077-2088.
7. Gustafson P, Willén H, Baldetorp B, et al. Soft tissue leiomyosarcoma. A population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content. Cancer 1992;70:114-119.
8. Farshid G, Pradhan M, Goldblum J, et al. Leiomyosarcoma of somatic soft tissues. A tumor of vascular origin with multivariate analysis of outcome in 42 cases. Am J Surg Pathol 2002;26:14-24.
9. Mankin HJ, Casas-Ganem J, Kim JI, et al. Leiomyosarcoma of somatic soft tissues. Clin Orthop Relat Res 2004;1:225-231.
10. Miyajima K, Oda Y, Oshiro Y, et al. Clinicopathological prognostic factors in soft tissue leiomyosarcoma: A multivariate analysis. Histopathology 2002;40:353-359.
11. Jensen ML, Jensen OM, Michalski W, et al. Intradermal and subcutaneous leiomyosarcoma: A clinicopathological and immunohistochemical study of 41 cases. J Cutan Pathol 1996;23:458-463.
12. Kaddu S, Beham A, Cerroni L, et al. Cutaneous leiomyosarcoma. Am J Surg Pathol 1997;21:979-987.
13. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Leiomyosarcoma. Cancer Genet Cytogenet 2005;161:1-19.
14. Mitelman F, Johansson B, Mertens F, (eds). Mitelman database of chromosome aberrations in cancer. 2006; http://cgap.nci.nih.gov/Chromosomes/ Mitelman.
15. Boghosian L, Dal Cin P, Turc-Carel C, et al. Three possible cytogenetic subgroups of leiomyosarcoma. Cancer Genet Cytogenet 1989;43:39-49.
16. Sreekantaiah C, Davis JR, Sandberg AA. Chromosomal abnormalities in leiomyosarcomas. Am J Pathol 1993;142:293-305.
17. Mertens F, Fletcher CD, Dal Cin P, et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP study group. Genes Chromosomes Cancer 1998;22:16-25.
18. Mandahl N, Fletcher CD, Dal Cin P, et al. Comparative cytogenetic study of spindle cell and pleomorphic leiomyosarcomas of soft tissues: a report from the CHAMP study group. Cancer Genet Cytogenet 2000;116:66-73.
19. Miyajima K, Oda Y, Tamiya S, et al. Cytogenetic and clinicopathological analysis of soft-tissue leiomyosarcomas. Pathol Int 2003;53:163-168.
20. Packenham JP, du Manoir S, Schrock E, et al. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization. Mol Carcinog 1997;19:273-279.
21. El-Rifai W, Sarlomo-Rikala M, Knuutila S, et al. DNA copy number changes in development and progression in leiomyosarcomas of soft tissues. Am J Pathol 1998;153:985-990.
22. Parente F, Grosgeorge J, Coindre JM, et al. Comparative genomic hybridization reveals novel chromosome deletions in 90 primary soft tissue tumors. Cancer Genet Cytogenet 1999;115:89-95.
23. Otaño-Joos M, Mechtersheimer G, Ohl S, et al. Detection of chromosomal imbalances in leiomyosarcoma by comparative genomic hybridization and interphase cytogenetics. Cytogenet Cell Genet 2000;90:86-92.
24. Levy B, Mukherjee T, Hirschhorn K. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization. Cancer Genet Cytogenet 2000;121:1-8.
25. Wang R, Lu YJ, Fisher C, et al. Characterization of chromosome aberrations associated with soft-tissue leiomyosarcomas by twenty-four-color karyotyping and comparative genomic hybridization analysis. Genes Chromosomes Cancer 2001;31:54-64.
26. Derré J, Lagace R, Nicolas A, et al. Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. Lab Invest 2001;81:211-215.
27. Hu J, Khanna V, Jones M, et al. Genomic alterations in uterine leiomyosarcomas: potential markers for clinical diagnosis and prognosis. Genes Chromosomes Cancer 2001;31:117-124.
28. Wang R, Titley JC, Lu YJ, et al. Loss of 13q14-q21 and gain of 5p14-pter in the progression of leiomyosarcoma. Mod Pathol 2003;16:778-785.
29. Giuntoli 2nd RL, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003;89:460-469.
30. Dinh TA, Oliva EA, Fuller Jr AF, et al. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol 2004;92:648-652.
31. Sutton G, Blessing J, Hanjani P, et al. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:749-752.
32. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994;18:535-558.
33. Isola J, DeVries S, Chu L, et al. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 1994;145:1301-1308.
34. Larramendy ML, Tarkkanen M, Valle J, et al. Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. Am J Pathol 1997;150:685-691.
35. El-Rifai W, Larramendy ML, Björkqvist AM, et al. Optimization of comparative genomic hybridization using fluorochrome conjugated to dCTP and dUTP nucleotides. Lab Invest 1997;77:699-700.
36. Larramendy ML, El-Rifai W, Knuutila S. Comparison of fluorescein isothiocyanate- and Texas red-conjugated nucleotides for direct labeling in comparative genomic hybridization. Cytometry 1998;31:174-179.
37. Kallioniemi OP, Kallioniemi A, Piper J, et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 1994;10:231-243.
38. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-537.
39. Chibon F, Mariani O, Mairal A, et al. The use of clustering software for the classification of comparative genomic hybridization data. An analysis of 109 malignant fibrous histiocytomas. Cancer Genet Cytogenet 2003;141:75-78.
40. Karpeh MS, Brennan MF, Cance WG, et al. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer 1995;72:986-991.
41. Knuutila S, Aalto Y, Autio K, et al. DNA copy number losses in human neoplasms. Am J Pathol 1999;155:683-694.
42. Dei Tos AP, Maestro R, Doglioni C, et al. Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol 1996;148:1037-1045.
43. Stratton MR, Williams S, Fisher C, et al. Structural alterations of the RB1 gene in human soft tissue tumours. Br J Cancer 1989;60:202-205.
44. Lee J, Li S, Torbenson M, Liu QZ, et al. Leiomyosarcoma of the breast: a pathologic and comparative genomic hybridization study of two cases. Cancer Genet Cytogenet 2004;149:53-57.
45. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947.
46. Quade BJ, Pinto AP, Howard DR, et al. Frequent loss of heterozygosity for chromosome 10 in uterine leiomyosarcoma in contrast to leiomyoma. Am J Pathol 1999;154:945-950.
47. Wechsler DS, Shelly CA, Dang CV. Genomic organization of human MXI1, a putative tumor suppressor gene. Genomics 1996;32:466-470.
48. Mayol X, Grana X, Baldi A, et al. Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene 1993;8:2561-2566.
49. Skubitz KM, Skubitz AP. Differential gene expression in leiomyosarcoma. Cancer 2003;98:1029-1038.
50. Knuutila S, Björkqvist AM, Autio K, et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 1998;152:1107-1123.
51. Tarkkanen M, Karhu R, Kallioniemi A, et al. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res 1995;55:1334-1338.
52. Forus A, Weghuis DO, Smeets D, et al. Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas. Genes Chromosomes Cancer 1995;14:15-21.
53. Larramendy ML, Tarkkanen M, Blomqvist C, et al. Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker. Am J Pathol 1997;151:1153-1161.
54. Szymanska J, Tarkkanen M, Wiklund T, et al. Gains and losses of DNA sequences in liposarcomas evaluated by comparative genomic hybridization. Genes Chromosomes Cancer 1996;15:89-94.
55. Armengol G, Tarkkanen M, Virolainen M, et al. Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer 1997;75:1403-1409.
56. Forus A, Berner JM, Meza-Zepeda LA, et al. Molecular characterization of a novel amplicon at 1q21-q22 frequently observed in human sarcomas. Br J Cancer 1998;78:495-503.
57. Forus A, Weghuis DO, Smeets D, et al. Comparative genomic hybridization analysis of human sarcomas: I. Occurrence of genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft tissue sarcomas. Genes Chromosomes Cancer 1995;14:8-14.
58. Forus A, D'Angelo A, Henriksen J, et al. Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity. Oncogene 2001;20:6881-6890.
59. Patterson H, Gill S, Fisher C, et al. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 1994;69:1052-1058.
60. Yoo J, Lee HK, Kang CS, et al. p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch Pathol Lab Med 1997;121:395-399.
61. Mittal K, Demopoulos RI. MIB-1 (ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol 2001;32:984-987.
62. Miyajima K, Tamiya S, Oda Y, et al. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction. Cancer Lett 2001;164:177-188.
63. Wolf M, Tarkkanen M, Hulsebos T, et al. Characterization of the 17p amplicon in human sarcomas: microsatellite marker analysis. Int J Cancer 1999;82:329-333.
64. Van Dartel M, Cornelissen PW, Redeker S, et al. Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma. Cancer Genet Cytogenet 2002;139:91-96.
65. Tarkkanen M, Elomaa I, Blomqvist C, et al. DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int J Cancer 1999;84:114-121.
66. Rieker RJ, Joos S, Bartsch C, et al. Distinct chromosomal imbalances in pleomorphic and in high-grade dedifferentiated liposarcomas. Int J Cancer 200;99:68-73.
67. Weissman AM. Regulating protein degradation by ubiquitination. Immunol Today 1997;18:189-198.
68. Tarkkanen M, Kiuru-Kuhlefelt S, Blomqvist C, et al. Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors. Cancer Genet Cytogenet 1999;114:35-41.
69. Skytting BT, Szymanska J, Aalto Y, et al. Clinical importance of genomic imbalances in synovial sarcoma evaluated by comparative genomic hybridization. Cancer Genet Cytogenet 1999;115:39-46.